Sarepta Therapeutics (NASDAQ:SRPT) Stock Price Up 5.9%

Sarepta Therapeutics, Inc. (NASDAQ:SRPT)’s stock price rose 5.9% during mid-day trading on Wednesday . The stock traded as high as $124.37 and last traded at $124.01. Approximately 550,813 shares changed hands during mid-day trading, a decline of 43% from the average daily volume of 972,684 shares. The stock had previously closed at $117.12.

Analyst Ratings Changes

SRPT has been the topic of several recent research reports. Needham & Company LLC cut their price target on Sarepta Therapeutics from $169.00 to $166.00 and set a “buy” rating on the stock in a report on Thursday, February 29th. Evercore ISI raised their target price on Sarepta Therapeutics from $108.00 to $138.00 and gave the company an “in-line” rating in a report on Tuesday, February 20th. Cantor Fitzgerald restated a “neutral” rating and issued a $128.00 target price on shares of Sarepta Therapeutics in a report on Thursday, February 29th. Mizuho raised their target price on Sarepta Therapeutics from $130.00 to $145.00 and gave the company a “buy” rating in a report on Wednesday, February 14th. Finally, Citigroup increased their price target on Sarepta Therapeutics from $160.00 to $172.00 and gave the company a “buy” rating in a research report on Thursday, February 29th. Four equities research analysts have rated the stock with a hold rating and twelve have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $158.38.

Sarepta Therapeutics Stock Performance

The company has a 50-day moving average of $126.11 and a 200 day moving average of $110.47. The company has a quick ratio of 3.45, a current ratio of 3.95 and a debt-to-equity ratio of 1.32. The firm has a market capitalization of $12.09 billion, a PE ratio of -21.04 and a beta of 0.94.

Sarepta Therapeutics (NASDAQ:SRPT) last posted its quarterly earnings data on Wednesday, February 28th. The biotechnology company reported $0.47 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.03) by $0.50. Sarepta Therapeutics had a negative return on equity of 18.97% and a negative net margin of 43.11%. The firm had revenue of $396.80 million during the quarter, compared to analysts’ expectations of $387.18 million. During the same period in the prior year, the business earned ($1.24) EPS. The company’s revenue for the quarter was up 53.6% compared to the same quarter last year. Equities research analysts predict that Sarepta Therapeutics, Inc. will post 2.13 EPS for the current year.

Insider Activity

In other news, Director Kathryn Jean Boor sold 761 shares of the business’s stock in a transaction dated Monday, March 11th. The stock was sold at an average price of $122.93, for a total value of $93,549.73. Following the completion of the sale, the director now owns 7,516 shares of the company’s stock, valued at approximately $923,941.88. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. In other Sarepta Therapeutics news, Director Kathryn Jean Boor sold 761 shares of the company’s stock in a transaction that occurred on Monday, March 11th. The stock was sold at an average price of $122.93, for a total transaction of $93,549.73. Following the completion of the transaction, the director now owns 7,516 shares of the company’s stock, valued at approximately $923,941.88. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Hans Lennart Rudolf Wigzell sold 15,000 shares of the company’s stock in a transaction that occurred on Friday, March 8th. The shares were sold at an average price of $123.25, for a total value of $1,848,750.00. Following the transaction, the director now directly owns 22,840 shares of the company’s stock, valued at approximately $2,815,030. The disclosure for this sale can be found here. In the last quarter, insiders sold 22,096 shares of company stock valued at $2,739,419. Insiders own 7.40% of the company’s stock.

Institutional Inflows and Outflows

Institutional investors have recently made changes to their positions in the company. Mather Group LLC. bought a new position in shares of Sarepta Therapeutics in the 1st quarter worth approximately $28,000. Montag A & Associates Inc. purchased a new stake in shares of Sarepta Therapeutics in the 3rd quarter worth approximately $30,000. Cary Street Partners Investment Advisory LLC grew its stake in shares of Sarepta Therapeutics by 154.0% in the 3rd quarter. Cary Street Partners Investment Advisory LLC now owns 254 shares of the biotechnology company’s stock worth $31,000 after buying an additional 154 shares during the last quarter. Principal Securities Inc. purchased a new stake in shares of Sarepta Therapeutics in the 4th quarter worth approximately $26,000. Finally, GAMMA Investing LLC grew its stake in shares of Sarepta Therapeutics by 37.0% in the 1st quarter. GAMMA Investing LLC now owns 322 shares of the biotechnology company’s stock worth $42,000 after buying an additional 87 shares during the last quarter. Institutional investors own 86.68% of the company’s stock.

Sarepta Therapeutics Company Profile

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.